Healthcare Industry News: Acute Coronary Syndrome
News Release - June 24, 2008
Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial OperationsSOUTH SAN FRANCISCO, Calif., June 24 (HSMN NewsFeed) -- Portola Pharmaceuticals, a clinical-stage biopharmaceutical developing best-in-class therapeutics for acute and chronic cardiovascular and inflammatory diseases, today announced that Bill Lis has joined the company as Vice President of Business and Commercial Development. Mr. Lis will be responsible for the company's corporate partnering activities as well as commercial strategy for Portola's portfolio of clinical and preclinical programs. He will join the company's executive management team.
Mr. Lis has over 17 years of experience in biopharmaceutical and medical device sales & marketing, medical affairs, and business development. From 2005 until 2008 he was Vice President, Business and New Product Development, Scios, Inc. (A Johnson and Johnson Company) where, most recently, he was responsible for cardiovascular business licensing strategies and activities and commercial operations. He led successful in-licensing activities and pre-market and commercial infrastructure development for Xarelto® (rivaroxaban) a Phase III drug candidate, filed for EMEA regulatory approval. Prior to joining Scios, he was Director of Marketing and New Products, Millennium Pharmaceuticals, Inc. where he held positions of increasing leadership, including the management of marketing activities for Integrilin® (eptifibatide), a best in class antithrombotic drug. Previously, at Rhone Poulenc Rorer and Ethicon Endo Surgery he was involved in the launch and commercialization of several products, including Lovenox® (enoxaparin). He holds a B.S. in Finance from the University of Maryland.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular disease. Portola has two antithrombotic drug candidates in Phase II clinical development. Portola's lead compound, betrixaban (PRT054021), is an oral Factor Xa inhibitor with target markets that include the prevention of venous thromboembolism after orthopedic surgery, for stroke prevention in patients with atrial fibrillation and for secondary prevention of myocardial infarction (MI) and stroke. Portola's other clinical compound, PRT060128, is an oral and intravenous ADP receptor antagonist being developed for patients with Acute Coronary Syndrome, for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention and for secondary prevention of MI and stroke. In addition, Portola has a robust preclinical pipeline targeting opportunities in thrombosis and hemostasis as well as in cancer and inflammatory diseases.
Source: Portola Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsU.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa(R) for Third Year
Portola Pharmaceuticals Announces the Establishment of a Permanent J-code for Andexxa by the Centers for Medicare & Medicaid Services, Effective July 1, 2020
New Data Demonstrates Andexxa(R) Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors